Glancy Prongay & Murray LLP Announces Securities Fraud Class Action Lawsuit against BioAge Labs, Inc.
On January 29, 2025, Glancy Prongay & Murray LLP, a leading national litigation law firm, announced that investors who suffered losses on their investments in BioAge Labs, Inc. (BioAge or the Company) (NASDAQ: BIOA) have the opportunity to lead the securities fraud class action lawsuit against the Company. The lawsuit alleges that BioAge and certain of its executives violated the Securities Exchange Act of 1934.
Background on BioAge Labs, Inc.
BioAge is a biotechnology company specializing in the development and commercialization of therapeutics for aging and age-related diseases. The Company’s mission is to extend human lifespan and improve its quality through the use of its proprietary technology platform.
The Allegations
The securities fraud class action lawsuit alleges that BioAge and certain of its executives made false and misleading statements regarding the Company’s business, operations, and financial condition. Specifically, the complaint alleges that the defendants failed to disclose material information about the Company’s clinical trials, regulatory issues, and financial condition.
Impact on Investors
As a result of these alleged misrepresentations, BioAge’s stock traded at artificially inflated prices, causing investors to suffer significant losses. If you purchased BioAge securities between [dates], you may be eligible to recover your losses through the securities fraud class action lawsuit.
Impact on the World
The securities fraud class action lawsuit against BioAge Labs, Inc. has far-reaching implications for the biotechnology industry as a whole. This case highlights the importance of transparency and accuracy in disclosing material information to investors. The lawsuit also raises awareness about the potential risks associated with investing in biotechnology companies, particularly those in the clinical trial stage.
Lead Plaintiff Deadline
If you suffered losses on your BioAge investments, you have until March 10, 2025, to request appointment as lead plaintiff in the securities fraud class action lawsuit. To be eligible, you must have purchased BioAge securities between [dates] and suffered losses as a result.
Contact Information
If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests, please contact Lesley Portnoy, Esquire, of Glancy Prongay & Murray LLP, or by email at [email protected], or by telephone at (310) 201-9150, or visit
Conclusion
The securities fraud class action lawsuit against BioAge Labs, Inc. serves as a reminder to investors to carefully evaluate the information provided by companies before making investment decisions. The case also highlights the importance of transparency and accuracy in disclosing material information to investors. If you believe you have suffered losses as a result of investing in BioAge securities, you may be eligible to recover your losses through the securities fraud class action lawsuit. Contact Glancy Prongay & Murray LLP for more information.
- Glancy Prongay & Murray LLP announces securities fraud class action lawsuit against BioAge Labs, Inc.
- Investors who suffered losses may be eligible to recover through the lawsuit.
- Allegations include false and misleading statements regarding clinical trials, regulatory issues, and financial condition.
- Impact on investors: artificially inflated stock prices leading to significant losses.
- Impact on the world: highlights importance of transparency and accuracy in disclosing material information to investors.
- Lead plaintiff deadline: March 10, 2025.
- Contact Glancy Prongay & Murray LLP for more information.
